A study on the induction of antitumor activity of rAd-p53 combined with immune checkpoint inhibitor (ICI) anti-PD-1 in a mouse homologous urogenital cancer model was reported in 2020 [25] and found that the combination of rAd-p53 and anti-PD-1 induced tumor-infiltrating T cells and that rAd-p53 increased PD-L1 expression in tumor cells in vivo. The gene discussed is TP53; the disease is urogenital neoplasm.